Form 4: Medpace President Sells Shares After Option Exercise

Medpace Holdings, Inc. President Jesse J. Geiger sold a total of 23,028 shares of common stock after exercising employee stock options.

Summary

• Jesse J. Geiger, President of Medpace Holdings, Inc., engaged in multiple transactions involving company stock.
• On October 27, 2025, Geiger exercised options to acquire 19,460 shares of common stock at an exercise price of $166.73 per share.
• Immediately following, Geiger sold 19,460 shares at a weighted average price of $605.12 per share, with individual sales ranging from $600.00 to $610.66.
• On October 29, 2025, Geiger exercised options to acquire an additional 3,568 shares of common stock at $166.73 per share.
• Concurrently, Geiger sold 3,568 shares at a price of $585 per share.
• All transactions were conducted pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Geiger directly beneficially owns 36,503 shares of Medpace Holdings, Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling based on undisclosed information. It represents a routine liquidity event for an executive.

Positives

• The options were exercised at a significantly lower price ($166.73) compared to the sale prices ($605.12 and $585), indicating substantial personal gain for the executive.
• The transactions were executed under a pre-arranged Rule 10b5-1(c) plan, suggesting the sales were not based on new, undisclosed material information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe a slight reduction in the President's direct equity stake, though the pre-planned nature of the sale under Rule 10b5-1(c) suggests no immediate negative implications regarding company performance or outlook.

Key Dates

Recommendation

The filing details routine insider transactions (option exercise and sale) executed under a Rule 10b5-1 plan. These pre-scheduled sales are common for executives managing their compensation and liquidity and do not typically signal a change in the company's fundamental outlook. Therefore, the filing itself does not provide new information warranting a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Medpace Holdings, MEDP, Jesse J. Geiger, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, Rule 10b5-1